ArticlePloS one2026
OncoSeg2D: A deep framework for semantic segmentation of lung cancer in 2D CT scans.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer lesion segmentation in two-dimensional computed tomography (2D CT) images remains challenging due to blurred boundaries, heterogeneous morphologies, and annotation uncertainty, leading to unreliable delineations and reduced clinical usability. To address this research gap, we propose a novel 2D CT lung cancer semantic segmentation framework, OncoSeg2D, which explicitly tackles boundary ambiguity and morphological distortion through two complementary modules. Specifically, an Uncertainty-aware Boundary Modeling (UBM) module probabilistically represents tumor edges via learnable mean-variance estimation and gradient-weighted sampling, while a Morphology-Preserving Regularization (MPR) module constrains the segmentation with curvature, compactness, and convexity priors to maintain global shape consistency. The framework integrates these designs with multi-scale feature extraction from a SegFormer backbone and requires no additional annotations or three-dimensional (3D) reconstruction. Experiments conducted on the Medical Segmentation Decathlon Challenge dataset and the lung cancer segmentation dataset demonstrate that OncoSeg2D achieves IoU scores of 0.865 and 0.788, mIoU scores of 0.881 and 0.799, and Dice Similarity Coefficients (DSC) of 0.923 and 0.816, consistently outperforming conventional CNN-based models and mainstream Transformer-based methods. Compared with the SegFormer baseline, the proposed method improves mIoU by 3.8% and 4.0% on the two datasets, respectively, while reducing the Hausdorff distance from 5.61 to 3.41 and from 7.26 to 5.28, indicating superior boundary refinement and stronger global shape consistency. These results verify that explicitly integrating uncertainty modeling and morphological priors yields both higher accuracy and better interpretability. Overall, the proposed framework not only enhances segmentation accuracy but also improves clinical interpretability and reliability, offering a promising solution for lung cancer diagnosis assistance and therapeutic outcome monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.